

18 August 2023

## PRE-QUOTATION DISCLOSURE

Cleo Diagnostics Ltd (ASX:COV) (**Company**) makes the following disclosures in accordance with ASX's listing conditions.

Capitalised terms not otherwise defined have the meaning given in the Company's replacement prospectus dated 6 July 2023 (**Replacement Prospectus**).

### 1. Completion of Hudson Licence Agreement

The Company confirms the conditions precedent under Hudson Licence Agreement have been satisfied (not waived) and completion has occurred, including the issue of 7,500,000 Shares to Hudson Institute Investment Holdings Pty Ltd as detailed in Section 7.1 of the Hudson Licence Agreement.

### 2. Issue of Options

The Company confirms that it has completed the issue of:

- (a) 5,000,000 unquoted Options exercisable at \$0.30 and expiring three years from the date of quotation to the Lead Manager (or its nominee) under the Lead Manager Offer;
- (b) 1,500,000 unquoted Options exercisable at \$0.30 and expiring three years from the date of quotation to iRX Advisors Pty Ltd (or its nominee); and
- (c) 7,500,000 unquoted Options exercisable at \$0.30 and expiring three years from the date of quotation to various directors and employees of the Company.

### 3. Restricted securities

The Company confirms that the following securities will be subject to restriction pursuant to the ASX Listing Rules for the period outlined below:

Class	Number	Restriction period
Shares	46,900,000	24 months from the date of official quotation
Shares	8,825,000	12 months from the date of issue
Options with an exercise price of \$0.30 each and expiring 3 years from the date of quotation	13,500,000	24 months from the date of official quotation

**Cleo Diagnostics Ltd** ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000  
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors  
Chair and Non-Executive Director: **Adrien Wing**  
Chief Executive Officer and Executive Director: **Dr Richard Allman**  
Chief Scientific Officer and Executive Director: **Dr Andrew Stephens**  
Non-Executive Director and Lead Medical Advisor: **Professor Tom Jobling**  
Non-Executive Director: **Lucinda Nolan**

cleodx.com

#### **4. Grant of patent application in the United States**

The Company provides an update on the disclosure in the Replacement Prospectus relating to the Company's patent application in the United States.

The Company confirms that on 15 August 2023 the United States Patent and Trademark Office granted the Company's patent application in the United States.

#### **By order of the Board**

Pauline Moffatt  
Company Secretary  
**Cleo Diagnostics Ltd**

